FX006 approval status: FX006 is currently being reviewed and evaluated for efficacy and safety by the FDA and is not approved for use outside of clinical trials.
Flexion is committed to supporting investigator-initiated research (IIR) to expand clinical and scientific knowledge about our lead product candidate FX006 and musculoskeletal disorders, particularly osteoarthritis. The IIR program is open to investigators who are interested in conducting their own independently sponsored research. IIR proposals may be clinical (interventional or observational) studies or nonclinical/basic research. Flexion thoroughly evaluates each IIR submission, taking into account parameters such as trial design and patient safety. Priority will be given to projects that aim to significantly contribute to clinical decision-making, support our medical strategies, and complement ongoing and planned internal research.
Investigators interested in submitting a concept or proposal to Flexion for consideration must fill out the required information below (e-mail submissions are not accepted). Please be advised that submission of research proposals – including those within Flexion areas of interest – does not imply or guarantee approval.